For Pharma Companies

MVI's immunotherapies can help companies define approvable combination regimens for checkpoint inhibitors, market-differentiated regimens with AR axis inhibitors, and position IDO axis inhibitors for success.
‍

Developing low cost, stable, simple to dose, immunoactive DNA plasmids offering safe and efficacious combination agents for use with checkpoint inhibitors
Clinically focused mindset with our eighth clinical trial underway
Therapies across three stages of prostate cancer: non-metastatic, biochemically-recurrent; metastatic, hormone-sensitive; and metastatic, castration-resistant
Two plasmid DNA vaccines available targeting PAP and AR
Differentiation of specific versions of ADT or AR inhibition in combination with MVI DNA plasmids (provides non-overlapping toxicities, synergistic activity in metastatic disease, ability to keep patients on AR blockade longer by delaying resistance)
Combinations and agent sequencing regimens tailored to the specific stage of prostate cancer
Strategy aligned with major stakeholders (patients, physicians, regulators, payers, and pharma/biotech)
Flexible partnering structures

We offer a singularly strong pipeline, with:

Our clinical data is revealing new immunosuppressive metabolic pathway activation, and we have a new combination Tx approach under development.

We have clinical trials in progress that are targeting:

In all trials, we have seen one or more of the following clinical signals:

We have a deep clinical biomarker database: